AtaGenix Laboratories
AtaGenix Laboratories
Release time: 2026-01-22 View volume: 10
Multi-target strategies, explosive market growth, and the rise of bispecific + ADC combinations — what it means for antibody developers.
From multi-billion-dollar licensing deals to next-generation combination strategies
Bispecific antibodies simultaneously engage two distinct targets — such as PD-1 immune checkpoints and VEGF-mediated angiogenesis — delivering synergistic antitumor effects and overcoming monotherapy resistance. Recent clinical programs combining bispecifics with ADCs represent the next frontier: multi-modality, precision immune modulation for solid tumors including NSCLC, CRC, and beyond.
Three converging markets driving demand for advanced antibody services
| U.S. Market (2024) | $11.78B |
| Projected (2033) | $271.95B |
| CAGR | 40.1% |
| Global Market (2026) | $14.76B |
| Projected (2035) | $32.66B |
| CAGR | 9.23% |
| Global Market (2025) | $608.75M |
| Projected (2033) | $1,297.65M |
| CAGR | 9.98% |
Sources: ResearchAndMarkets, SNS Insider, industry reports
The convergence of bispecific antibodies and ADCs is reshaping oncology. Projects combining dual-target engagement with cytotoxic payloads demonstrate that multi-modality strategies can significantly improve clinical outcomes. AtaGenix provides end-to-end services — from antibody discovery through stable cell line construction — to help you move faster from concept to clinic.
Discuss Your Project →AtaGenix · Professional Antibody Development & Protein Expression Services · © 2026
Contact Us
+86-27-6552-3339
info@atagenix.com
Building C, R & D Building, No. 666, Shendun 4th Road, Donghu New Technology Development Zone, Wuhan
